These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

803 related articles for article (PubMed ID: 17277339)

  • 1. Implementation of 'K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease' after the introduction of cinacalcet in a population of patients on chronic haemodialysis.
    Arenas MD; Alvarez-Ude F; Gil MT; Moledous A; Malek T; Nuñez C; Devesa R; Carretón MA; Soriano A
    Nephrol Dial Transplant; 2007 Jun; 22(6):1639-44. PubMed ID: 17277339
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
    Lorenzo Sellares V; Torregrosa V
    Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early initiation of cinacalcet for the treatment of secondary hyperparathyroidism in hemodialysis patients: a three-year clinical experience.
    Lucchi L; Carboni C; Stipo L; Malaguti V; Ferrari F; Graziani R; Arletti S; Graziosi C
    Artif Organs; 2011 Dec; 35(12):1186-93. PubMed ID: 21848793
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Application of NKF-K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease: changes of clinical practices and their effects on outcomes and quality standards in three haemodialysis units.
    Arenas MD; Alvarez-Ude F; Gil MT; Soriano A; Egea JJ; Millán I; Amoedo ML; Muray S; Carretón MA
    Nephrol Dial Transplant; 2006 Jun; 21(6):1663-8. PubMed ID: 16464885
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined therapy with cinacalcet and low doses of vitamin D sterols in patients with moderate to severe secondary hyperparathyroidism.
    Block GA; Zeig S; Sugihara J; Chertow GM; Chi EM; Turner SA; Bushinsky DA;
    Nephrol Dial Transplant; 2008 Jul; 23(7):2311-8. PubMed ID: 18310602
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cinacalcet and achievement of the NKF/K-DOQI recommended target values for bone and mineral metabolism in real-world clinical practice--the ECHO observational study.
    Ureña P; Jacobson SH; Zitt E; Vervloet M; Malberti F; Ashman N; Leavey S; Rix M; Os I; Saha H; Ryba M; Bencova V; Baños A; Zani V; Fouque D
    Nephrol Dial Transplant; 2009 Sep; 24(9):2852-9. PubMed ID: 19369690
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Economic analysis of cinacalcet in combination with low-dose vitamin D versus flexible-dose vitamin D in treating secondary hyperparathyroidism in hemodialysis patients.
    Shireman TI; Almehmi A; Wetmore JB; Lu J; Pregenzer M; Quarles LD
    Am J Kidney Dis; 2010 Dec; 56(6):1108-16. PubMed ID: 20951487
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Consequences of the implementation of K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease in a population of patients on chronic hemodialysis.
    Arenas MD; Alvarez-Ude F; Torregrosa V; Gil MT; Carretón MA; Moledous A; Nuñez C; Devesa R; Albiach B
    J Nephrol; 2007; 20(4):453-61. PubMed ID: 17879212
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of vitamin D dose on biochemical parameters in patients with secondary hyperparathyroidism receiving cinacalcet.
    Wilkie M; Pontoriero G; Macário F; Yaqoob M; Bouman K; Braun J; von Albertini B; Brink H; Maduell F; Graf H; Frazão JM; Bos WJ; Torregrosa V; Saha H; Reichel H; Zani VJ; Carter D; Messa P
    Nephron Clin Pract; 2009; 112(1):c41-50. PubMed ID: 19365139
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Survey of attitudes of physicians toward the current evaluation and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD).
    Souqiyyeh MZ; Shaheen FA
    Saudi J Kidney Dis Transpl; 2010 Jan; 21(1):93-101. PubMed ID: 20061700
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cinacalcet HCl: a novel treatment for secondary hyperparathyroidism caused by chronic kidney disease.
    Torres PU
    J Ren Nutr; 2006 Jul; 16(3):253-8. PubMed ID: 16825031
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cinacalcet hydrochloride (Sensipar) in hemodialysis patients on active vitamin D derivatives with controlled PTH and elevated calcium x phosphate.
    Chertow GM; Blumenthal S; Turner S; Roppolo M; Stern L; Chi EM; Reed J;
    Clin J Am Soc Nephrol; 2006 Mar; 1(2):305-12. PubMed ID: 17699221
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cinacalcet HCl and concurrent low-dose vitamin D improves treatment of secondary hyperparathyroidism in dialysis patients compared with vitamin D alone: the ACHIEVE study results.
    Fishbane S; Shapiro WB; Corry DB; Vicks SL; Roppolo M; Rappaport K; Ling X; Goodman WG; Turner S; Charytan C
    Clin J Am Soc Nephrol; 2008 Nov; 3(6):1718-25. PubMed ID: 18945995
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adherence to K/DOQI guidelines for calcium-based phosphate binders in clinical practice.
    Shastri J; Tran A; Covit A; Pepe J; Sherman RA
    J Ren Nutr; 2008 Jul; 18(4):370-4. PubMed ID: 18558302
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cinacalcet hydrochloride therapy for secondary hyperparathyroidism in hemodialysis patients.
    El-Shafey EM; Alsahow AE; Alsaran K; Sabry AA; Atia M
    Ther Apher Dial; 2011 Dec; 15(6):547-55. PubMed ID: 22107691
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Analysis of the efficacy and factors influencing the response of secondary hyperparathyroidism patients on hemodialysis to cinacalcet].
    Segura Torres P; Borrego Utiel FJ; Sánchez Perales MC; García Cortés MJ; Biechy Baldán MM; Pérez Bañasco V
    Nefrologia; 2010; 30(4):443-51. PubMed ID: 20651886
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of phosphorus and calcium metabolism and its clinical management in hemodialysis patients in the community of Valencia.
    Maduell F; Gorriz JL; Pallardo LM; Pons R; Santiago C;
    J Nephrol; 2005; 18(6):739-48. PubMed ID: 16358233
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The OPTIMA study: assessing a new cinacalcet (Sensipar/Mimpara) treatment algorithm for secondary hyperparathyroidism.
    Messa P; Macário F; Yaqoob M; Bouman K; Braun J; von Albertini B; Brink H; Maduell F; Graf H; Frazão JM; Bos WJ; Torregrosa V; Saha H; Reichel H; Wilkie M; Zani VJ; Molemans B; Carter D; Locatelli F
    Clin J Am Soc Nephrol; 2008 Jan; 3(1):36-45. PubMed ID: 18178780
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Achieving NKF-K/DOQI bone metabolism and disease treatment goals with cinacalcet HCl.
    Moe SM; Chertow GM; Coburn JW; Quarles LD; Goodman WG; Block GA; Drüeke TB; Cunningham J; Sherrard DJ; McCary LC; Olson KA; Turner SA; Martin KJ
    Kidney Int; 2005 Feb; 67(2):760-71. PubMed ID: 15673327
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 41.